Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of dual therapy containing vonopranzan and amoxicillin as first line Helicobacter pylori eradication: a randomized, non-inferiority trial

Next Previous
Trial Profile

Efficacy and safety of dual therapy containing vonopranzan and amoxicillin as first line Helicobacter pylori eradication: a randomized, non-inferiority trial

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amoxicillin (Primary) ; Clarithromycin (Primary) ; Vonoprazan (Primary)
  • Indications Helicobacter pylori infections
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 09 Jun 2021 Results (n=59) assessing lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication published in the Journal of Gastroenterology and Hepatology
    • 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020.
    • 08 Jan 2020 Primary endpoint (The primary outcome of this study is H. pylori eradication rates in the dual therapy and the standard triple therapy groups) has been met as per Results published in the Gut.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top